Genzyme formally rejects a $69-a-share buyout offer made by Sanofi-Aventis, saying it undervalues the biotechnology company.
MarketWatch.com - Top Stories, MarketWatch
Mon, 08/30/2010 - 9:00am
Genzyme formally rejects a $69-a-share buyout offer made by Sanofi-Aventis, saying it undervalues the biotechnology company.